

PRESS RELEASE

30 November 2007

Aperio Diagnostic Ltd appoints CEO

Medical diagnostic company Aperio has appointed Sameer Kothari as its CEO.

Sameer brings over 15 years commercial experience to Aperio, which is currently developing real-time diagnostics for cervical cancer. Prior to joining Aperio, Sameer was CEO of Plasso Technology Ltd, a venture capital-backed company developing research tools and labware for the life sciences where he led a successful trade sale exit to Becton Dickinson Inc.

The technology underpinning Aperio Diagnostic Ltd is being developed in partnership with Exomedica Ltd, the medical technology development company.

Andrew Newell, Managing Director of Exomedica, commented: "I am delighted Sameer has agreed to join Aperio Diagnostic Limited as we enter our commercialisation phase. His experience and expertise will be invaluable in helping guide the board to further develop the strategy and delivering on our plan."

For more information please contact:

Sameer Kothari, CEO, Aperio Diagnostic Ltd, tel: 0114 222 4580; mobile: 07736 403872

Notes for editors:

Aperio Diagnostic Ltd is a company developing the next generation of cancer diagnostics with a product line which will provide real-time diagnostics for cervical cancer. Two products are under development: the first for the referral market and the second for the screening market. Clinical data on 500 women has demonstrated superior performance over existing diagnostic procedures and a multi-centre clinical trial over the next 8 months is expected to underwrite the effectiveness of Aperio's technology and products.

Aperio has developed Electrical Impedance Spectroscopy EIS, an objective scientifically-proven method to differentiate between normal, pre cancerous and cancerous cells. This provides a real-time diagnosis that removes subjectivity at both screening and referral, and potentially avoids the need for a biopsy. Aperio's patented technology, which has been discussed in learned peer-reviewed journals, exploits the different electrical resistivity of normal, pre-cancerous and cancerous cells.

Since incorporation in 2006, Aperio has focused on developing a research-based instrument into a device appropriate for commercial manufacture and routine use by medical practitioners. Both Aperio products consist of a handheld device and a base unit together with a single-use disposable sleeve for each test. Pre-production standard devices will be used in a multi centre clinical trial scheduled to start in Q3 2008.